UNSPSC 51183201: Alogliptin

This classification denotes an anti-diabetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) JHC049LO86. European Medicines Agency schedules Alogliptin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32564. Alogliptin generally arises in the molecular formula C18H21N5O2.

The term ALOGLIPTIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 21, no. 3, 2007, list 58.) Most nations, for tariff and trade purposes, schedule alogliptin under HS 29335990 and SITC 51576. As of Q4 2014, ALOGLIPTIN remains US FDA's Preferred Term for this commodity. Alogliptin bears US NLM identifiers UMLS ID C1958126 and NCI Concept Code C76906. SMILES: CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCCC(C3)N.

UNSPSC 51183201 Alogliptin is a Commodity code covering individual pharmaceutical products supplied through state and local cooperative purchasing arrangements. State and local governments procure alogliptin and similar generic pharmaceuticals through multistate cooperative contracts that aggregate demand across dozens of participating jurisdictions and establish standing agreements with manufacturers for volume pricing and reliable supply to authorized wholesalers. The work being solicited is manufacturer supply of FDA-compliant pharmaceutical products with certified Good Manufacturing Practices (cGMP) compliance and Drug Supply Chain Security Act (DSCSA) certification, with pricing submitted through multiple formats (flat price, net price, or WAC-minus structures) and fulfillment through a curated set of authorized drug wholesalers. Issuing bodies include state procurement offices administering cooperative purchasing vehicles and the member jurisdictions they serve—states, counties, municipalities, and special-purpose health systems across the country.

The most recent activity centers on the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, which issued an RFP (S1070000015802) on January 20, 2026 for generic multi-source pharmaceuticals and over-the-counter products with a March 26, 2026 response deadline. The RFP covers participating states including Oregon and requires vendors to maintain contractual relationships with authorized wholesalers AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC, with awarded vendors taking effect July 1, 2026 for a two-year term. MMCAP evaluation weights price competitiveness at 75 percent and requires vendors to carry commercial general liability insurance of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000, with a 3 percent administrative fee on all contract purchases and performance penalties of $200 to $1,500 per violation.